HROW
HARROW, INC.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$27.68
+1.47%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$27.63
From 52W high−49.49%
Volume563882.00
Market cap$1.04B
P/E (TTM)—
P/S (TTM)3.8x
Div yield—
Key dataOct 19, 2026
Open
$27.63
From 52W high
−49.49%
Volume
563882.00
Market cap
$1.04B
ValuationView details →
P/E (Fwd)
16.6x
EV/EBITDA
112.1x
P/E (TTM)
—
RSI (14)
34.9
MomentumView details →
1D Return
+1.47%
YTD Return
−42.04%
SummaryUpdated Jun 1, 2026
Harrow Health, Inc. (NASDAQ:HROW) is a specialty pharmaceutical company focused on the ophthalmology market. Originally incorporated in 2006 as Imprimis Pharmaceuticals, the company rebranded to Harrow Health in December 2018 to reflect its broader healthcare focus. Based in San Diego, California, Harrow has evolved from a compounding pharmacy business into a diversified ophthalmic pharmaceutical company that develops, manufactures, and commercializes prescription drugs for eye care professionals and their patients across North America.
Similar companies
Latest newsMore news →
Harrow, Inc. and Viatris Inc. signed a side letter under which Viatris will pay tiered royalties on Japanese net sales of TYRVAYA and the parties will negotiate a collaboration for Viatris's R&D, manufacture and commercialization of TYRVAYA in Japan.15d agoHarrow, Inc. acquired the TYRVAYA rights in all countries except Japan from Viatris Inc. for $30.0 million in cash, with up to $70.0 million in contingent milestone payments.15d agoHarrow closed its acquisition of TYRVAYA, the first and only FDA-approved nasal spray for dry eye disease, adding a drop-free treatment option to its ocular surface franchise.15d ago